Leap Therapeutics, Inc. (NASDAQ:LPTX) Expected to Announce Earnings of -$0.11 Per Share

Equities analysts predict that Leap Therapeutics, Inc. (NASDAQ:LPTX – Get Rating) will post ($0.11) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Leap Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.10) and the lowest estimate coming in at ($0.13). Leap Therapeutics posted earnings per share of ($0.12) in the same quarter last year, which suggests a positive year over year growth rate of 8.3%. The company is scheduled to issue its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Leap Therapeutics will report full-year earnings of ($0.45) per share for the current fiscal year, with EPS estimates ranging from ($0.49) to ($0.41). For the next year, analysts expect that the company will post earnings of ($0.51) per share, with EPS estimates ranging from ($0.61) to ($0.39). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that cover Leap Therapeutics.

Leap Therapeutics (NASDAQ:LPTX – Get Rating) last issued its quarterly earnings data on Friday, March 11th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.01. Leap Therapeutics had a negative net margin of 2,705.80% and a negative return on equity of 55.42%.

Separately, Zacks Investment Research raised shares of Leap Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 price target on the stock in a report on Thursday, March 17th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $4.00.

Shares of NASDAQ:LPTX opened at $1.59 on Friday. The firm has a 50 day moving average of $1.88 and a 200-day moving average of $2.42. The stock has a market capitalization of $140.43 million, a PE ratio of -3.31 and a beta of 0.56. Leap Therapeutics has a 12 month low of $1.33 and a 12 month high of $4.17.

Several institutional investors have recently bought and sold shares of LPTX. FMR LLC increased its position in Leap Therapeutics by 63.3% during the 1st quarter. FMR LLC now owns 1,563,124 shares of the company’s stock valued at $2,923,000 after purchasing an additional 606,000 shares during the period. Morgan Stanley increased its position in Leap Therapeutics by 426,666.7% during the 1st quarter. Morgan Stanley now owns 38,409 shares of the company’s stock valued at $73,000 after purchasing an additional 38,400 shares during the period. Citadel Advisors LLC acquired a new stake in Leap Therapeutics during the 2nd quarter valued at approximately $53,000. International Assets Investment Management LLC acquired a new stake in Leap Therapeutics during the 3rd quarter valued at approximately $40,000. Finally, Valeo Financial Advisors LLC acquired a new stake in Leap Therapeutics during the 3rd quarter valued at approximately $52,000. 61.55% of the stock is currently owned by institutional investors.

About Leap Therapeutics (Get Rating)

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers.

See Also